{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:19:17Z","timestamp":1794071957537,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIA","award":["R01AG069901"],"award-info":[{"award-number":["R01AG069901"]}]},{"name":"NIA","award":["R01AG046171"],"award-info":[{"award-number":["R01AG046171"]}]},{"name":"Emory EHBS","award":["R01 AG070937"],"award-info":[{"award-number":["R01 AG070937"]}]},{"name":"Emory ADRC","award":["P30 AG066511"],"award-info":[{"award-number":["P30 AG066511"]}]},{"DOI":"10.13039\/100000009","name":"FNIH","doi-asserted-by":"crossref","award":["DAOU16AMPA"],"award-info":[{"award-number":["DAOU16AMPA"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"crossref"}]},{"name":"USDA","award":["2032-51530-022-00D"],"award-info":[{"award-number":["2032-51530-022-00D"]}],"id":[{"id":"https:\/\/ror.org\/01na82s61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Integration of the omics data, including metabolomics and proteomics, provides a unique opportunity to search for new associations within metabolic disorders, including Alzheimer\u2019s disease. Using metabolomics, we have previously profiled oxylipins, endocannabinoids, bile acids, and steroids in 293 CSF and 202 matched plasma samples from AD cases and healthy controls and identified both central and peripheral markers of AD pathology within inflammation-regulating cytochrome p450\/soluble epoxide hydrolase pathway. Additionally, using proteomics, we have identified five cerebrospinal fluid protein panels, involved in the regulation of energy metabolism, vasculature, myelin\/oligodendrocyte, glia\/inflammation, and synapses\/neurons, affected in AD, and reflective of AD-related changes in the brain. In the current manuscript, using metabolomics-proteomics data integration, we describe new associations between peripheral and central lipid mediators, with the above-described CSF protein panels. Particularly strong associations were observed between cytochrome p450\/soluble epoxide hydrolase metabolites, bile acids, and proteins involved in glycolysis, blood coagulation, and vascular inflammation and the regulators of extracellular matrix. Those metabolic associations were not observed at the gene-co-expression level in the central nervous system. In summary, this manuscript provides new information regarding Alzheimer\u2019s disease, linking both central and peripheral metabolism, and illustrates the necessity for the \u201comics\u201d data integration to uncover associations beyond gene co-expression.<\/jats:p>","DOI":"10.1038\/s41598-023-39737-8","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T05:29:10Z","timestamp":1692768550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Integration of plasma and CSF metabolomics with CSF proteomic reveals novel associations between lipid mediators and central nervous system vascular and energy metabolism"],"prefix":"10.1038","volume":"13","author":[{"given":"Kamil","family":"Borkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas T.","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Lah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan I.","family":"Levey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadwick M.","family":"Hales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Dammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Blach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Kaddurah-Daouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"39737_CR1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.aca.2020.10.038","volume":"1141","author":"MA Worheide","year":"2021","unstructured":"Worheide, M. A. et al. Multi-omics integration in biomedical research\u2014A metabolomics-centric review. Anal. Chim. Acta 1141, 144\u2013162 (2021).","journal-title":"Anal. Chim. Acta"},{"issue":"1","key":"39737_CR2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-021-00814-7","volume":"13","author":"C Clark","year":"2021","unstructured":"Clark, C. et al. An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer\u2019s disease. Alzheimers Res. Ther. 13(1), 71 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"39737_CR3","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101346","volume":"69","author":"H Hampel","year":"2021","unstructured":"Hampel, H. et al. Omics sciences for systems biology in Alzheimer\u2019s disease: State-of-the-art of the evidence. Ageing Res. Rev. 69, 101346 (2021).","journal-title":"Ageing Res. Rev."},{"issue":"9","key":"39737_CR4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jalz.2017.01.020","volume":"13","author":"JB Toledo","year":"2017","unstructured":"Toledo, J. B. et al. Metabolic network failures in Alzheimer\u2019s disease: A biochemical road map. Alzheimers Dement. 13(9), 965\u2013984 (2017).","journal-title":"Alzheimers Dement."},{"key":"39737_CR5","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2018.263","volume":"5","author":"DK Barupal","year":"2018","unstructured":"Barupal, D. K. et al. Generation and quality control of lipidomics data for the Alzheimer\u2019s disease neuroimaging initiative cohort. Sci. Data 5, 180263 (2018).","journal-title":"Sci. Data"},{"key":"39737_CR6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney, J. W. et al. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement. (N Y) 4, 575\u2013590 (2018).","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"1","key":"39737_CR7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13195-021-00893-6","volume":"13","author":"K Borkowski","year":"2021","unstructured":"Borkowski, K. et al. Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer\u2019s disease. Alzheimers Res. Ther. 13(1), 149 (2021).","journal-title":"Alzheimers Res. Ther."},{"issue":"5","key":"39737_CR8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3945\/an.114.007732","volume":"6","author":"M Gabbs","year":"2015","unstructured":"Gabbs, M. et al. Advances in our understanding of oxylipins derived from dietary PUFAs. Adv. Nutr. 6(5), 513\u2013540 (2015).","journal-title":"Adv. Nutr."},{"issue":"3","key":"39737_CR9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0090-6980(92)90096-C","volume":"43","author":"I Schimke","year":"1992","unstructured":"Schimke, I. et al. Effects of reactive oxygen species on eicosanoid metabolism in human endothelial cells. Prostaglandins 43(3), 281\u2013292 (1992).","journal-title":"Prostaglandins"},{"issue":"6","key":"39737_CR10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2826.2008.01728.x","volume":"20","author":"L Bellocchio","year":"2008","unstructured":"Bellocchio, L. et al. The endocannabinoid system and energy metabolism. J. Neuroendocrinol. 20(6), 850\u2013857 (2008).","journal-title":"J. Neuroendocrinol."},{"key":"39737_CR11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pneurobio.2017.10.007","volume":"160","author":"V Chiurchiu","year":"2018","unstructured":"Chiurchiu, V. et al. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Prog. Neurobiol. 160, 82\u2013100 (2018).","journal-title":"Prog. Neurobiol."},{"issue":"12","key":"39737_CR12","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","volume":"173","author":"SE O'Sullivan","year":"2016","unstructured":"O\u2019Sullivan, S. E. An update on PPAR activation by cannabinoids. Br. J. Pharmacol. 173(12), 1899\u20131910 (2016).","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"39737_CR13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3390\/ijms19030833","volume":"19","author":"S Zou","year":"2018","unstructured":"Zou, S. & Kumar, U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci. 19(3), 833 (2018).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"39737_CR14","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cphy.c120023","volume":"3","author":"JY Chiang","year":"2013","unstructured":"Chiang, J. Y. Bile acid metabolism and signaling. Compr. Physiol. 3(3), 1191\u20131212 (2013).","journal-title":"Compr. Physiol."},{"key":"39737_CR15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/164_2019_236","volume":"256","author":"DJ Shin","year":"2019","unstructured":"Shin, D. J. & Wang, L. Bile acid-activated receptors: A review on FXR and other nuclear receptors. Handb. Exp. Pharmacol. 256, 51\u201372 (2019).","journal-title":"Handb. Exp. Pharmacol."},{"key":"39737_CR16","first-page":"646","volume":"7","author":"C Guo","year":"2016","unstructured":"Guo, C., Chen, W. D. & Wang, Y. D. TGR5, not only a metabolic regulator. Front. Physiol. 7, 646 (2016).","journal-title":"Front. Physiol."},{"issue":"43","key":"39737_CR17","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.1126\/sciadv.aaz9360","volume":"6","author":"L Higginbotham","year":"2020","unstructured":"Higginbotham, L. et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease. Sci. Adv. 6(43), 9360 (2020).","journal-title":"Sci. Adv."},{"issue":"3\u20134","key":"39737_CR18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000501856","volume":"53","author":"ME Goetz","year":"2019","unstructured":"Goetz, M. E. et al. Rationale and design of the Emory healthy aging and Emory healthy brain studies. Neuroepidemiology 53(3\u20134), 187\u2013200 (2019).","journal-title":"Neuroepidemiology"},{"issue":"4","key":"39737_CR19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw, L. M. et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann. Neurol. 65(4), 403\u2013413 (2009).","journal-title":"Ann. Neurol."},{"issue":"8","key":"39737_CR20","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert, F. et al. Improved discrimination of AD patients using beta-amyloid(1\u201342) and tau levels in CSF. Neurology 52(8), 1555\u20131562 (1999).","journal-title":"Neurology"},{"key":"39737_CR21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.aca.2020.11.019","volume":"1143","author":"TL Pedersen","year":"2021","unstructured":"Pedersen, T. L., Gray, I. J. & Newman, J. W. Plasma and serum oxylipin, endocannabinoid, bile acid, steroid, fatty acid and nonsteroidal anti-inflammatory drug quantification in a 96-well plate format. Anal. Chim. Acta 1143, 189\u2013200 (2021).","journal-title":"Anal. Chim. Acta"},{"issue":"5","key":"39737_CR22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41591-020-0815-6","volume":"26","author":"ECB Johnson","year":"2020","unstructured":"Johnson, E. C. B. et al. Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med. 26(5), 769\u2013780 (2020).","journal-title":"Nat. Med."},{"issue":"1","key":"39737_CR23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57(1), 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"issue":"6","key":"39737_CR24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"Consortium G.T.","year":"2013","unstructured":"Consortium G.T. The genotype-tissue expression (GTEx) project. Nat. Genet. 45(6), 580\u2013585 (2013).","journal-title":"Nat. Genet."},{"issue":"2","key":"39737_CR25","volume":"32","author":"YW Wan","year":"2020","unstructured":"Wan, Y. W. et al. Meta-analysis of the Alzheimer\u2019s disease human brain transcriptome and functional dissection in mouse models. Cell Rep. 32(2), 107908 (2020).","journal-title":"Cell Rep."},{"key":"39737_CR26","unstructured":"W\u00f6rheide, M.A. et al. An integrated molecular atlas of Alzheimer\u2019s disease. medRxiv: 2021.09.14.21263565 (2021)."},{"issue":"1","key":"39737_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03602532.2020.1858856","volume":"53","author":"W Kuban","year":"2021","unstructured":"Kuban, W. & Daniel, W. A. Cytochrome P450 expression and regulation in the brain. Drug Metab. Rev. 53(1), 1\u201329 (2021).","journal-title":"Drug Metab. Rev."},{"key":"39737_CR28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-030-50621-6_5","volume":"1274","author":"C McReynolds","year":"2020","unstructured":"McReynolds, C. et al. Epoxy fatty acids are promising targets for treatment of pain, cardiovascular disease and other indications characterized by mitochondrial dysfunction, endoplasmic stress and inflammation. Adv. Exp. Med. Biol. 1274, 71\u201399 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"39737_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plefa.2017.10.006","volume":"128","author":"GC Shearer","year":"2018","unstructured":"Shearer, G. C. et al. Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 128, 1\u201310 (2018).","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"issue":"1","key":"39737_CR30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s40495-017-0117-y","volume":"4","author":"AI Lalani","year":"2018","unstructured":"Lalani, A. I. et al. TRAF molecules in inflammation and inflammatory diseases. Curr. Pharmacol. Rep. 4(1), 64\u201390 (2018).","journal-title":"Curr. Pharmacol. Rep."},{"issue":"6","key":"39737_CR31","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2353\/ajpath.2009.080544","volume":"174","author":"AN Simpkins","year":"2009","unstructured":"Simpkins, A. N. et al. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am. J. Pathol. 174(6), 2086\u20132095 (2009).","journal-title":"Am. J. Pathol."},{"key":"39737_CR32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0090-6980(02)00031-X","volume":"68\u201369","author":"NG Bazan","year":"2002","unstructured":"Bazan, N. G., Colangelo, V. & Lukiw, W. J. Prostaglandins and other lipid mediators in Alzheimer\u2019s disease. Prostaglandins Other Lipid Mediat. 68\u201369, 197\u2013210 (2002).","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"4","key":"39737_CR33","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/ijms21041505","volume":"21","author":"YC Kao","year":"2020","unstructured":"Kao, Y. C. et al. Lipids and Alzheimer\u2019s disease. Int. J. Mol. Sci. 21(4), 1505 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"39737_CR34","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.3390\/ijms21165783","volume":"21","author":"K Miyazawa","year":"2020","unstructured":"Miyazawa, K. et al. Alzheimer\u2019s disease and specialized pro-resolving lipid mediators: Do MaR1, RvD1, and NPD1 show promise for prevention and treatment?. Int. J. Mol. Sci. 21(16), 5783 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"39737_CR35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jalz.2018.07.217","volume":"15","author":"S MahmoudianDehkordi","year":"2019","unstructured":"MahmoudianDehkordi, S. et al. Altered bile acid profile associates with cognitive impairment in Alzheimer\u2019s disease\u2014An emerging role for gut microbiome. Alzheimers Dement. 15(1), 76\u201392 (2019).","journal-title":"Alzheimers Dement."},{"issue":"8","key":"39737_CR36","volume":"1","author":"P Baloni","year":"2020","unstructured":"Baloni, P. et al. Metabolic network analysis reveals altered bile acid synthesis and metabolism in Alzheimer\u2019s disease. Cell Rep. Med. 1(8), 100138 (2020).","journal-title":"Cell Rep. Med."},{"key":"39737_CR37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fnagi.2016.00263","volume":"8","author":"HD Ackerman","year":"2016","unstructured":"Ackerman, H. D. & Gerhard, G. S. Bile acids in neurodegenerative disorders. Front. Aging Neurosci. 8, 263 (2016).","journal-title":"Front. Aging Neurosci."},{"key":"39737_CR38","doi-asserted-by":"crossref","unstructured":"Ghosh, A. et al. Epoxy fatty acid dysregulation and neuroinflammation in Alzheimer\u2019s disease is resolved by a soluble epoxide hydrolase inhibitor. bioRxiv: 2020.06.30.180984 (2020).","DOI":"10.1101\/2020.06.30.180984"},{"issue":"2","key":"39737_CR39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41588-020-00773-z","volume":"53","author":"AP Wingo","year":"2021","unstructured":"Wingo, A. P. et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer\u2019s disease pathogenesis. Nat. Genet. 53(2), 143\u2013146 (2021).","journal-title":"Nat. Genet."},{"issue":"1","key":"39737_CR40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1152\/physrev.00021.2011","volume":"92","author":"JD Imig","year":"2012","unstructured":"Imig, J. D. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 92(1), 101\u2013130 (2012).","journal-title":"Physiol. Rev."},{"issue":"1","key":"39737_CR41","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.1038\/s41598-019-45005-5","volume":"9","author":"A Rajamani","year":"2019","unstructured":"Rajamani, A. et al. Oxylipins in triglyceride-rich lipoproteins of dyslipidemic subjects promote endothelial inflammation following a high fat meal. Sci. Rep. 9(1), 8655 (2019).","journal-title":"Sci. Rep."},{"issue":"5","key":"39737_CR42","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/jcm8050651","volume":"8","author":"K Govindpani","year":"2019","unstructured":"Govindpani, K. et al. Vascular dysfunction in Alzheimer\u2019s disease: A prelude to the pathological process or a consequence of it?. J. Clin. Med. 8(5), 651 (2019).","journal-title":"J. Clin. Med."},{"issue":"2","key":"39737_CR43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.yjmcc.2009.10.022","volume":"48","author":"Y Deng","year":"2010","unstructured":"Deng, Y., Theken, K. N. & Lee, C. R. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J. Mol. Cell Cardiol. 48(2), 331\u2013341 (2010).","journal-title":"J. Mol. Cell Cardiol."},{"issue":"3","key":"39737_CR44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney, M. D., Sagare, A. P. & Zlokovic, B. V. Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14(3), 133\u2013150 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"39737_CR45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fphar.2019.00036","volume":"10","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto, K. Role of soluble epoxide hydrolase in metabolism of PUFAs in psychiatric and neurological disorders. Front. Pharmacol. 10, 36 (2019).","journal-title":"Front. Pharmacol."},{"key":"39737_CR46","doi-asserted-by":"publisher","unstructured":"Ghosh, A. et al. Epoxy fatty acid dysregulation and neuroinflammation in Alzheimer\u2019s disease is resolved by a soluble epoxide hydrolase inhibitor. BioRxiv. https:\/\/doi.org\/10.1101\/2020.06.30.180984 (2020).","DOI":"10.1101\/2020.06.30.180984"},{"key":"39737_CR47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","volume":"180","author":"KM Wagner","year":"2017","unstructured":"Wagner, K. M. et al. Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol. Ther. 180, 62\u201376 (2017).","journal-title":"Pharmacol. Ther."},{"key":"39737_CR48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jnutbio.2019.03.004","volume":"68","author":"K Borkowski","year":"2019","unstructured":"Borkowski, K. et al. Walnuts change lipoprotein composition suppressing TNFalpha-stimulated cytokine production by diabetic adipocyte. J. Nutr. Biochem. 68, 51\u201358 (2019).","journal-title":"J. Nutr. Biochem."},{"issue":"20","key":"39737_CR49","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1074\/jbc.M113.458414","volume":"288","author":"A Bettaieb","year":"2013","unstructured":"Bettaieb, A. et al. Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue. J. Biol. Chem. 288(20), 14189\u201314199 (2013).","journal-title":"J. Biol. Chem."},{"key":"39737_CR50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fphar.2016.00133","volume":"7","author":"MK Akhnokh","year":"2016","unstructured":"Akhnokh, M. K. et al. Inhibition of soluble epoxide hydrolase limits mitochondrial damage and preserves function following ischemic injury. Front. Pharmacol. 7, 133 (2016).","journal-title":"Front. Pharmacol."},{"issue":"22","key":"39737_CR51","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1073\/pnas.1103482108","volume":"108","author":"A Luria","year":"2011","unstructured":"Luria, A. et al. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc. Natl. Acad. Sci. USA 108(22), 9038\u20139043 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"39737_CR52","volume":"296","author":"J Luo","year":"2021","unstructured":"Luo, J. et al. Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney. J. Biol. Chem. 296, 100667 (2021).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"39737_CR53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbrc.2005.03.171","volume":"331","author":"K Ohtoshi","year":"2005","unstructured":"Ohtoshi, K. et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem. Biophys. Res. Commun. 331(1), 347\u2013350 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"39737_CR54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389202911314020003","volume":"14","author":"S Haider","year":"2013","unstructured":"Haider, S. & Pal, R. Integrated analysis of transcriptomic and proteomic data. Curr. Genomics 14(2), 91\u2013110 (2013).","journal-title":"Curr. Genomics"},{"issue":"13","key":"39737_CR55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4239\/wjd.v7.i13.260","volume":"7","author":"H Taoka","year":"2016","unstructured":"Taoka, H. et al. Role of bile acids in the regulation of the metabolic pathways. World J. Diabetes 7(13), 260\u2013270 (2016).","journal-title":"World J. Diabetes"},{"key":"39737_CR56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fnins.2017.00617","volume":"11","author":"KL Mertens","year":"2017","unstructured":"Mertens, K. L. et al. Bile acid signaling pathways from the enterohepatic circulation to the central nervous system. Front. Neurosci. 11, 617 (2017).","journal-title":"Front. Neurosci."},{"key":"39737_CR57","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016203","volume":"296","author":"T Sasaki","year":"2021","unstructured":"Sasaki, T. et al. Muscle-specific TGR5 overexpression improves glucose clearance in glucose-intolerant mice. J. Biol. Chem. 296, 100131 (2021).","journal-title":"J. Biol. Chem."},{"issue":"2","key":"39737_CR58","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MEG.0b013e32835a86f3","volume":"25","author":"M Magnusson","year":"2013","unstructured":"Magnusson, M. et al. Bile acids and coagulation factors: Paradoxical association in children with chronic liver disease. Eur. J. Gastroenterol. Hepatol. 25(2), 152\u2013158 (2013).","journal-title":"Eur. J. Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39737-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T12:49:48Z","timestamp":1729946988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39737-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39737"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-39737-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kaddurah-Daouk in an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia LLC and PsyProtix, which were not involved in this study. Matthias Arnold is co-inventor (through Duke University\/Helmholtz Zentrum M\u00fcnchen) on patents on applications of metabolomics in diseases of the central nervous system. Matthias Arnold also holds equity in Chymia LLC and IP in PsyProtix and Atai that is unrelated to this work. Kamil Borkowski (through Duke University\/UC Davis) is a coinventor on a patent of targeting lipid mediators in Alzheimer\u2019s disease. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13752"}}